On October 19, 2021 Cannabics Pharmaceuticals Inc. (OTC: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, reported that Company CEO, Eyal Barad, will present at the upcoming Edison Open Forum: Cannabinoids 2021, taking place today, Wednesday, October 19th (Press release, Cannabics Pharmaceuticals, OCT 19, 2021, View Source [SID1234592177]). Mr. Barad’s talk will focus on the pharmaceutical development of synthetic cannabinoid-based drug candidates for colorectal cancer and other cancers designated for FDA regulatory review.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Eyal Barad, Cannabics Pharmaceuticals Co-Founder and CEO said: "We are proud to have been selected to present at Edison’s Open Forum Conference and share our perspective on synthetic cannabinoid drug development and on the challenges, opportunities and trends we see in the industry."
To access the Forum and the presentation please register at the following link: